Robert W. Baird Upgrades Vor Biopharma (NASDAQ:VOR) to “Outperform”

Vor Biopharma (NASDAQ:VORGet Free Report) was upgraded by stock analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a research report issued on Wednesday, MarketBeat reports. The firm presently has a $64.00 price target on the stock, up from their prior price target of $20.00. Robert W. Baird’s price target would suggest a potential upside of 120.23% from the stock’s previous close.

VOR has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Zacks Research cut shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday. Wall Street Zen cut shares of Vor Biopharma to a “strong sell” rating in a research report on Saturday, June 28th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Vor Biopharma has a consensus rating of “Hold” and a consensus price target of $77.83.

View Our Latest Report on VOR

Vor Biopharma Stock Performance

VOR stock opened at $29.06 on Wednesday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The firm’s fifty day simple moving average is $36.80. The company has a market cap of $199.06 million, a price-to-earnings ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VORGet Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insider Activity at Vor Biopharma

In other news, major shareholder Reprogrammed Interchange Llc sold 33,668 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $30.32, for a total value of $1,020,813.76. Following the completion of the sale, the insider directly owned 1,278,118 shares of the company’s stock, valued at approximately $38,752,537.76. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 1,117,860 shares of company stock valued at $24,894,078. Company insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Vor Biopharma in the 1st quarter worth about $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma in the 1st quarter worth about $100,000. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the 2nd quarter worth about $66,000. Finally, Money Concepts Capital Corp increased its stake in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares in the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

Featured Stories

Analyst Recommendations for Vor Biopharma (NASDAQ:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.